| Original language | English (US) |
|---|---|
| Pages (from-to) | 491-502 |
| Number of pages | 12 |
| Journal | Surgical Pathology Clinics |
| Volume | 15 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2022 |
Keywords
- Cancer screening
- Genetic testing
- Germline mutations
- Immunotherapy
- Multigene panel testing
- PARP inhibitors
- Pancreatic ductal adenocarcinoma
ASJC Scopus subject areas
- Surgery
- Pathology and Forensic Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Surgical Pathology Clinics, Vol. 15, No. 3, 09.2022, p. 491-502.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice
AU - Mohindroo, Chirayu
AU - De Jesus-Acosta, Ana
AU - Yurgelun, Matthew B.
AU - Maitra, Anirban
AU - Mork, Maureen
AU - McAllister, Florencia
N1 - Funding Information: A. Maitra receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and monitored by the UTMDACC Conflict of Interest Committee. A. Maitra is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to Thrive Earlier Detection. A. Maitra is a consultant for Freenome and Tezcat Biotechnology. F. McAllister is an SAB Member at Neologics Bio.M.B. Yurgelun receives research funding from Janssen Pharmaceuticals. Funding Information: This study was supported by grants to F. McAllister from the NCI (1R37CA237384–01A1), CPRIT (RP200173), V Foundation Translational Award, Andrew Sabin Family Fellowship, SU2C-Lustgarten Foundation Pancreatic Cancer Interception Translational Cancer Research Grant (Grant Number: SU2C-AACR-DT25-17).and philanthropic support from the MD Anderson Moonshot Programs. A. Maitra is supported by the Khalifa Bin Zayed Al-Nahyan Foundation and P50CA221707. A. Maitra receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and monitored by the UTMDACC Conflict of Interest Committee. A. Maitra is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to Thrive Earlier Detection. A. Maitra is a consultant for Freenome and Tezcat Biotechnology. F. McAllister is an SAB Member at Neologics Bio.M.B. Yurgelun receives research funding from Janssen Pharmaceuticals. Funding Information: This study was supported by grants to F. McAllister from the NCI ( 1R37CA237384–01A1 ), CPRIT (RP200173), V Foundation Translational Award, Andrew Sabin Family Fellowship, SU2C-Lustgarten Foundation Pancreatic Cancer Interception Translational Cancer Research Grant (Grant Number: SU2C-AACR-DT25-17).and philanthropic support from the MD Anderson Moonshot Programs. A. Maitra is supported by the Khalifa Bin Zayed Al-Nahyan Foundation and P50CA221707.
PY - 2022/9
Y1 - 2022/9
KW - Cancer screening
KW - Genetic testing
KW - Germline mutations
KW - Immunotherapy
KW - Multigene panel testing
KW - PARP inhibitors
KW - Pancreatic ductal adenocarcinoma
UR - http://www.scopus.com/inward/record.url?scp=85135332733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135332733&partnerID=8YFLogxK
U2 - 10.1016/j.path.2022.05.004
DO - 10.1016/j.path.2022.05.004
M3 - Review article
C2 - 36049831
AN - SCOPUS:85135332733
SN - 1875-9181
VL - 15
SP - 491
EP - 502
JO - Surgical Pathology Clinics
JF - Surgical Pathology Clinics
IS - 3
ER -